Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

The flavonoid Baicalein attenuates cuprizone-induced demyelination via suppression of neuroinflammation.

Hashimoto M, Yamamoto S, Iwasa K, Yamashina K, Ishikawa M, Maruyama K, Bosetti F, Yoshikawa K.

Brain Res Bull. 2017 Oct;135:47-52. doi: 10.1016/j.brainresbull.2017.09.007. Epub 2017 Sep 15.

PMID:
28923306
2.

A Novel Aza-MBP Altered Peptide Ligand for the Treatment of Experimental Autoimmune Encephalomyelitis.

Trager NNM, Butler JT, Harmon J, Mount J, Podbielska M, Haque A, Banik NL, Beeson CC.

Mol Neurobiol. 2018 Jan;55(1):267-275. doi: 10.1007/s12035-017-0739-4.

PMID:
28889362
3.

Serum Neuroinflammatory Disease-Induced Central Nervous System Proteins Predict Clinical Onset of Experimental Autoimmune Encephalomyelitis.

Raphael I, Webb J, Gomez-Rivera F, Chase Huizar CA, Gupta R, Arulanandam BP, Wang Y, Haskins WE, Forsthuber TG.

Front Immunol. 2017 Jul 17;8:812. doi: 10.3389/fimmu.2017.00812. eCollection 2017.

4.

Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease.

Yamamoto S, Yamashina K, Ishikawa M, Gotoh M, Yagishita S, Iwasa K, Maruyama K, Murakami-Murofushi K, Yoshikawa K.

J Neuroinflammation. 2017 Jul 21;14(1):142. doi: 10.1186/s12974-017-0923-5.

5.

Mechanism of oxidative stress p38MAPK-SGK1 signaling axis in experimental autoimmune encephalomyelitis (EAE).

Wang L, Li B, Quan MY, Li L, Chen Y, Tan GJ, Zhang J, Liu XP, Guo L.

Oncotarget. 2017 Jun 27;8(26):42808-42816. doi: 10.18632/oncotarget.17057.

6.

Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.

Xiao J, Yang R, Biswas S, Zhu Y, Qin X, Zhang M, Zhai L, Luo Y, He X, Mao C, Deng W.

Mol Neurobiol. 2017 May 2. doi: 10.1007/s12035-017-0566-7. [Epub ahead of print] Review.

PMID:
28466274
7.

Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate.

D Alessandro J, Garofalo K, Zhao G, Honan C, Duffner J, Capila I, Fier I, Kaundinya G, Kantor D, Ganguly T.

CNS Neurol Disord Drug Targets. 2017;16(6):714-723. doi: 10.2174/1871527316666170223162747.

8.

Gene therapy with mesenchymal stem cells expressing IFN-ß ameliorates neuroinflammation in experimental models of multiple sclerosis.

Marin-Bañasco C, Benabdellah K, Melero-Jerez C, Oliver B, Pinto-Medel MJ, Hurtado-Guerrero I, de Castro F, Clemente D, Fernández O, Martin F, Leyva L, Suardíaz M.

Br J Pharmacol. 2017 Feb;174(3):238-253. doi: 10.1111/bph.13674. Epub 2017 Jan 12.

9.

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination.

Evonuk KS, Moseley CE, Doyle RE, Weaver CT, DeSilva TM.

J Vis Exp. 2016 Sep 12;(115). doi: 10.3791/54348.

10.

Environmental factors in autoimmune diseases and their role in multiple sclerosis.

Jörg S, Grohme DA, Erzler M, Binsfeld M, Haghikia A, Müller DN, Linker RA, Kleinewietfeld M.

Cell Mol Life Sci. 2016 Dec;73(24):4611-4622. Epub 2016 Aug 4. Review.

11.

Increased plasma levels of epithelial neutrophil-activating peptide 78/CXCL5 during the remission of Neuromyelitis optica.

Yang T, Wang S, Zheng Q, Wang L, Li Q, Wei M, Du Z, Fan Y.

BMC Neurol. 2016 Jul 11;16:96. doi: 10.1186/s12883-016-0622-3.

12.

A mouse model for testing remyelinating therapies.

Bai CB, Sun S, Roholt A, Benson E, Edberg D, Medicetty S, Dutta R, Kidd G, Macklin WB, Trapp B.

Exp Neurol. 2016 Sep;283(Pt A):330-40. doi: 10.1016/j.expneurol.2016.06.033. Epub 2016 Jul 3.

13.

Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.

Brändle SM, Obermeier B, Senel M, Bruder J, Mentele R, Khademi M, Olsson T, Tumani H, Kristoferitsch W, Lottspeich F, Wekerle H, Hohlfeld R, Dornmair K.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7864-9. doi: 10.1073/pnas.1522730113. Epub 2016 Jun 20.

14.

Multiple sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptor.

Rühl G, Niedl AG, Patronov A, Siewert K, Pinkert S, Kalemanov M, Friese MA, Attfield KE, Antes I, Hohlfeld R, Dornmair K.

Neurol Neuroimmunol Neuroinflamm. 2016 May 17;3(4):e241. doi: 10.1212/NXI.0000000000000241. eCollection 2016 Aug.

15.

Inherited and acquired disorders of myelin: The underlying myelin pathology.

Duncan ID, Radcliff AB.

Exp Neurol. 2016 Sep;283(Pt B):452-75. doi: 10.1016/j.expneurol.2016.04.002. Epub 2016 Apr 9. Review.

16.

Double Roles of Macrophages in Human Neuroimmune Diseases and Their Animal Models.

Fan X, Zhang H, Cheng Y, Jiang X, Zhu J, Jin T.

Mediators Inflamm. 2016;2016:8489251. doi: 10.1155/2016/8489251. Epub 2016 Mar 13. Review.

17.

Advancing Cardiovascular, Neurovascular, and Renal Magnetic Resonance Imaging in Small Rodents Using Cryogenic Radiofrequency Coil Technology.

Niendorf T, Pohlmann A, Reimann HM, Waiczies H, Peper E, Huelnhagen T, Seeliger E, Schreiber A, Kettritz R, Strobel K, Ku MC, Waiczies S.

Front Pharmacol. 2015 Nov 12;6:255. doi: 10.3389/fphar.2015.00255. eCollection 2015. Review.

18.

Stage-Specific Role of Interferon-Gamma in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.

Arellano G, Ottum PA, Reyes LI, Burgos PI, Naves R.

Front Immunol. 2015 Sep 29;6:492. doi: 10.3389/fimmu.2015.00492. eCollection 2015. Review.

19.

Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models.

Kihara Y, Groves A, Rivera RR, Chun J.

Ann Clin Transl Neurol. 2015 Oct;2(10):978-83. doi: 10.1002/acn3.251. Epub 2015 Sep 11.

20.

Recombinant human PDCD5 (rhPDCD5) protein is protective in a mouse model of multiple sclerosis.

Xiao J, Liu W, Chen Y, Deng W.

J Neuroinflammation. 2015 Jun 12;12:117. doi: 10.1186/s12974-015-0338-0.

Supplemental Content

Support Center